Banner image placeholder
Banner image
Site avatar

A. Alex Levine, PhD, MPH

Disability and Aging Researcher

The health benefits, costs, and cost-effectiveness of ultraorphan drugs


Journal article


Katherine A Clifford, A Alex Levine, Daniel E Enright, Peter J Neumann, James D Chambers
Value in Health, vol. 27, Elsevier, 2024, pp. 1656--1661

Cite

Cite

APA   Click to copy
Clifford, K. A., Levine, A. A., Enright, D. E., Neumann, P. J., & Chambers, J. D. (2024). The health benefits, costs, and cost-effectiveness of ultraorphan drugs. Value in Health, 27, 1656–1661.


Chicago/Turabian   Click to copy
Clifford, Katherine A, A Alex Levine, Daniel E Enright, Peter J Neumann, and James D Chambers. “The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan Drugs.” Value in Health 27 (2024): 1656–1661.


MLA   Click to copy
Clifford, Katherine A., et al. “The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan Drugs.” Value in Health, vol. 27, Elsevier, 2024, pp. 1656–61.


BibTeX   Click to copy

@article{clifford2024a,
  title = {The health benefits, costs, and cost-effectiveness of ultraorphan drugs},
  year = {2024},
  journal = {Value in Health},
  pages = {1656--1661},
  publisher = {Elsevier},
  volume = {27},
  author = {Clifford, Katherine A and Levine, A Alex and Enright, Daniel E and Neumann, Peter J and Chambers, James D}
}


Share

Translate to